← Browse by Condition
Medical Condition

neuroendocrine tumors

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for neuroendocrine tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuroendocrine tumors Clinical Trials

How many clinical trials are currently recruiting for neuroendocrine tumors?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for neuroendocrine tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroendocrine tumors?
neuroendocrine tumors research spans Phase 1 (3 trials), Phase 2 (5 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroendocrine tumors clinical trial?
Eligibility criteria for neuroendocrine tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
5
Phase 3
2
Top Sponsors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 trial
National Cancer Institute (NCI) 1 trial
University of Florida 1 trial
Teclison Ltd. 1 trial
University of California, San Francisco 1 trial

Recruiting Clinical Trials

NCT04166006 Phase 2
Recruiting
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Enrollment
51 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud...
View Trial →
NCT03412877 Phase 2
Recruiting
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Enrollment
285 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05000294 Phase 1, Phase 2
Recruiting
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Enrollment
29 pts
Location
United States
Sponsor
University of Florida
View Trial →
NCT02174549 Phase 1, Phase 2
Recruiting
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Enrollment
25 pts
Location
United States
Sponsor
Teclison Ltd.
View Trial →
NCT05746208 Phase 2
Recruiting
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Enrollment
29 pts
Location
United States
Sponsor
University of California, San ...
View Trial →
NCT05918302 Phase 3
Recruiting
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Enrollment
170 pts
Location
Belgium, France, Ita...
Sponsor
Grupo Espanol de Tumores Neuro...
View Trial →
NCT06937112
Recruiting
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Enrollment
20 pts
Location
China
Sponsor
Nanjing First Hospital, Nanjin...
View Trial →
NCT04706910 Phase 3
Recruiting
18F-DOPA II - PET Imaging Optimization
Enrollment
800 pts
Location
Canada
Sponsor
University of Alberta
View Trial →
NCT06505824 Phase 1
Recruiting
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Enrollment
115 pts
Location
China
Sponsor
Biokin (Shanghai) Biopharmaceu...
View Trial →

Related Conditions

soft tissue sarcoma (2) ovarian cancer (2) breast cancer (2) head neck tumors (1) rare cancer (1) vaccination (1) endocrine tumors (1) non small cell lung cancer (1) gastrointestinal genitourinary cancers (1) multiple myeloma (1) bile duct cancer (1) gall bladder cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology